Table 1.
The changes in relevant tumor markers throughout the treatment process
| Items | 2022-07-13 | 2022-09-03 | 2023-05-25 | 2023-10-27 | 2023-12-12 | 2024-01-30 | 2024-02-29 | 2024-04-09 |
|---|---|---|---|---|---|---|---|---|
| AFP (ng/ml)(< 7.0) | 565.5 | 2000 + | NA | 247.2 | 7.4 | 24.2 | 30.7 | 19.4 |
| CEA (ng/ml)(< 5.0) | 1.2 | 2.5 | 4.1 | 2.6 | 3.2 | 4.8 | 3.0 | 2.1 |
| CA15-3 (U/ml)(< 20.0) | NA | NA | 19.5 | NA | NA | 23.2 | 22.8 | 17.2 |
| CA12-5 (U/ml)(< 24.0) | 15.0 | 48.6 | 10.3 | NA | 33.9 | 44.3 | NA | NA |
| CA19-9 (U/ml)(< 30.0) | 14.9 | 3.2 | 12.9 | 11.8 | 18.1 | NA | NA | NA |
AFP Alpha-Fetoprotein, CEA carcinoembryonic antigen, CA15-3 Cancer Antigen 15–3; CA12-5 Cancer Antigen 12–5, CA19-9, Cancer Antigen 19–9